Mark Jeffrey DeLong - 10 Feb 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Business & Strat Officer
Signature
/s/ David Watson, attorney-in-fact for Mark DeLong
Issuer symbol
APLS
Transactions as of
10 Feb 2023
Net transactions value
-$34,311
Form type
4
Filing time
14 Feb 2023, 15:24:12 UTC
Previous filing
30 Jan 2023
Next filing
22 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Tax liability $34,311 -670 -1.4% $51.21 46,502 10 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares withheld for tax on a restricted stock unit release.